Our Story

Corporate Leadership

History

Our Mission

Vision, Mission, Values

Compliance and Accreditation

News

Our People

Why Work Here?

Employment Opportunities

Corporate Leadership

Our Products

Product Catalog

Serialization & DSCSA

EDI Capabilities & Processing

Complaints & Adverse Events

Collaboration

ANTI-CAPITAL PUNISHMENT STATEMENT

In fulfilling our mission to provide affordable, necessary medicines to enhance and save the lives of patients, XGen Pharmaceuticals DJB has always objected to and will continue to object to the use of our products in capital punishment.

Business Partnerships

XGen Pharmaceuticals DJB, Inc. values its heritage of progressive product line expansion and excellence in developing new partnerships. As a privately-owned business, XGen DJB distinguishes itself in the generic pharmaceutical market-space by placing emphasis on the development of key partnerships with domestic and internationally directed organizations.

Our product offerings center on generic injectables, distributed primarily through the hospital/clinic/institutional market; with a predominant focus on the US market.

We partner in areas that compliment our existing product offerings while expanding our reach beyond anti-infectives. Growth areas of interest include but are not limited to oncology, parental nutritional supplements, chronic disease, cardiology and neurology.

XGen values current relationships and actively seeks new collaborations in areas key to XGen’s growth, including

Asset purchases and licensing (ANDA, NDA)
Sales, marketing and distribution of approved products in the United States
Joint product development (ANDA, 505(b)(2), PIV)
Product lifecycle management (Including regulatory support – ANDA filings, Pharmacovigilance, etc.)
International registrations

Kim Johnson

VP, Quality Assurance

“We will consistently provide products of exceptional quality that meet, or exceed all ethical, technical and regulatory standards in the markets we serve.”